Fluticasone- vs Budesonide-Based Dual Therapy for COPD - PubMed
3 days ago
- #Inhalers
- #COPD
- #Clinical Outcomes
- The study compares the effectiveness of three ICS-LABA inhalers for COPD: fluticasone furoate-vilanterol (once-daily dry powder), fluticasone propionate-salmeterol (twice-daily dry powder), and budesonide-formoterol (twice-daily metered-dose).
- Fluticasone furoate-vilanterol showed a 9% lower risk of moderate or severe COPD exacerbations compared to budesonide-formoterol and a 6% lower risk compared to fluticasone propionate-salmeterol.
- No significant differences were observed in the risk of pneumonia hospitalization among the three inhaler types.
- The study suggests that once-daily dry powder fluticasone furoate-vilanterol may offer slightly better clinical outcomes for COPD patients compared to the other two inhalers.
- Further research is needed to explore potential differences within the ICS-LABA class for COPD treatment.